Drug intelligence / Profile preview

bifidobacterium longum + lactobacillus acidophilus + enterococcus faecalis

Development stage: Preclinical
Lead developer: Xinyi Pharmaceutical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium longum + Lactobacillus acidophilus + Enterococcus faecalis is an orally administered live biotherapeutic product, available as a capsule under the brand name BIFICO. It is being investigated in clinical trials by the First Affiliated Hospital of Xi'an Jiaotong University for the management of chronic kidney disease (CKD), particularly in patients on hemodialysis. The therapeutic rationale is based on addressing the gut dysbiosis commonly observed in CKD patients. This imbalance leads to an overproduction of uremic toxins, such as indoxyl-sulfate and p-cresyl sulfate, and contributes to systemic inflammation. By introducing these three beneficial bacterial strains, the probiotic aims to restore a healthier gut microbiota, which in turn is expected to reduce the production of these toxins, decrease inflammation, and improve the integrity of the intestinal barrier, potentially slowing the progression of CKD and its complications. The product is manufactured by Sine Pharmaceuticals.

Brand names: BIFICO
Other names: Bifid Triple Viable Capsules

Beyond the preview

Go deeper on bifidobacterium longum + lactobacillus acidophilus + enterococcus faecalis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium longum + lactobacillus acidophilus + enterococcus faecalis.

Explore the full profile